Manish Goel
About Manish Goel
SEBI Registered Research Analyst • Chartered Accountant
377 Articles Published
Manish Goel is a Chartered Accountant, SEBI Registered Research Analyst, and founder of Manish Goel PMS. A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.
May 23, 2026
Marathon Asset Management's Capital Cycle Theory tells Indian value investors to count plants, not consumers — the supply-side framework that predicts industry returns better than any demand forecast.
May 22, 2026
Iyengar & Lepper’s 2000 jam study and Sethi-Iyengar’s 2004 401(k) evidence show that wider option sets paralyse decision-makers. With ~1,500 MF schemes and 5,000+ listed stocks, Indian retail investors face an extreme choice-overload landscape. A four-step counter-measure checklist, and an educational case study on how Titan Biotech (BSE: 524717) FY25’s focused specialty-biotech portfolio reads as anti-choice-overload corporate behaviour.
May 22, 2026
The CEO-to-Median-Employee Pay Ratio mandated by Companies Act Section 197(12) read with Rule 5(1)(i) is one of the highest signal-to-noise governance disclosures in any Indian annual report. This educational piece decodes the metric, shows how to read its three-to-five-year arc, and illustrates the disciplined Pattern-A signature using Titan Biotech (BSE: 524717) FY25 audited markers — purely as a teaching case, not as a buy/sell view.
May 22, 2026
Christopher Mayer's 365-stock empirical study extracted seven attributes that predicted 100x compounders. Titan Biotech FY25 illustrates five of the seven on a small-cap Indian balance sheet.